CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 58 enrolled
Drug / intervention
Bepotastine besilatedrug
Likely dose
Bepotastine besilate 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01900054
NCT01900054Phase 3Completed
CompareCT.gov

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Tanabe Pharma Corporation·interventional·Posted Jul 16, 2013·Updated Jan 7, 2026

In Brief

A Phase 3 clinical trial evaluating Bepotastine besilate for Perennial Allergic Rhinitis. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 16, 2013
Enrollment StartJun 1, 2013
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.0 years ago

Interventions

Bepotastine besilatedrug

Two TAU-284 5mg tablets will be taken orally twice a day